Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Germany's Bayer  said on Thursday it was targeting growth in adjusted core profit of up to 9.6% this year, driven by sales of agriculture products and pharmaceuticals.

Bayer targets 9.6% gain in 2020 adjusted EBITDA

The departure of Bayer  Chairman Werner Wenning will turn up the heat on CEO Werner Baumann to resolve the healthcare to agriculture group's legal problems, two of the firm's biggest German shareholders said on Wednesday.

Pressure mounts on Bayer CEO to fix legal problems as chairman quits

Bayer  Chairman Werner Wenning, one of the architects of a $63 billion takeover deal that has left the German crop protection company fighting costly lawsuits, will step down in April, it said on Wednesday.

Bayer chairman quits as Roundup settlement talks progress

Bayer announced it found a new herbicide molecule, which is in Phase 2 of early development. The company explains that it offers a new herbicide post-emergence mode of action for the first time in 30 years.

Bayer Finds New Herbicide Molecule Amid More Lawsuits

BASF SE

A Missouri jury's $265 million award to peach grower Bill Bader in his lawsuit against herbicide providers Bayer and BASF has raised the stakes for the two companies as at least 140 similar cases head to U.S. courts later this year.

U.S. farmer wins $265 million weedkiller award from Bayer, BASF lawsuit

German agrochemicals group Bayer said on Sunday it would appeal a U.S. jury's $265 million damages award against it and BASF in favor of a Missouri farmer who said the company's dicamba herbicide had destroyed his peach orchards.

Bayer to appeal $265 million U.S. damages award on dicamba weedkiller

Bayer AG's  shares have taken a hit since three consecutive U.S. juries awarded more than $2 billion in damages to cancer patients alleging that the company's glyphosate-based weed killer, Roundup, caused their disease.

Factbox: Bayer faces lengthy Roundup appeals and settlement talks continue

As Bayer AG  tries to settle U.S. lawsuits claiming that its weedkiller Roundup causes cancer, the company is considering a proposal that would bar plaintiffs' lawyers involved in the litigation from advertising for new clients,  according to a person familiar with the matter.

Bayer considers new tactic in Roundup settlement talks

Bayer (BAYRY) files application to the FDA for the new formulation of nifurtimox to improve the body-weight adjusted dosing in pediatric Chagas patients.

Bayer Seeks FDA Approval for New Formulation of Nifurtimox

Both Johnson & Johnson as well as Pfizer could face new competition in the prostate cancer market.

Bayer's Prostate Cancer Drug Scores a Late-Stage Clinical Win

Bayer  is considering stopping sales of the weedkiller glyphosate to private users who apply it in their gardens, German newspaper Handelsblatt reported on Thursday, citing financial and corporate sources.

Bayer considering stopping sales of glyphosate to private users: newspaper

I Am Buying More Bayer Shares Because My Thesis Seems To Be Proving True

Bayer AG's (OTC: BAYRY) shares surged early Friday on Frankfurt stock exchange on rumors of possible settlements with tens of thousands of plaintiffs in its Roundup cancer case.

Bayer Trades Higher As Company Reportedly Talks $10B Roundup Cancer Case Settlement

In an effort to settle tens of thousands of claims that Bayer Roundup weedkiller causes cancer, lawyers for some plaintiffs are discussing with the company.
The post Bayer Discusses Settling Roundup Claims For $10 Billion appeared first on Investor's Business Daily.

Bayer Discusses Settling Roundup Claims For $10 Billion

Shares in seeds and pesticides maker Bayer  opened 2.3% higher on Friday, driven by a report on a possible out-of-court settlement of a U.S. jury trial over allegations that its weed killer Roundup causes cancer.

Bayer Shares up 2.3% on report about possible glyphosate settlement

Bayer AG  is set to face a fourth U.S. jury trial over allegations that its popular weed killer Roundup causes cancer, with four cancer patients in the hometown of its agricultural subsidiary Monsanto scheduled to make their case beginning on Friday.

Bayer faces fourth U.S. Roundup cancer trial in Monsanto home court

Despite getting approval in the U.S. and Canada, European counterparts weren't impressed by Vitraki.

Bayer's Cancer Drug Vitraki Rejected by Both England and Germany

Bayer  could be close to settling more than 75,000 cancer claims related to its Roundup herbicide, with mediator Ken Feinberg on Friday saying he was "cautiously optimistic that a settlement will ultimately be reached."

Bayer could be close to Roundup settlement, mediator says

Bayer  is close to settling more than 75,000 cancer claims related to its Roundup herbicide, mediator Ken Feinberg told Bloomberg in an interview, saying he was "cautiously optimistic" a deal could be reached in about a month.

Bayer close to Roundup settlement, mediator tells Bloomberg

Bayer: The Spectre Of Monsanto Conceals The Bargain Here

Bayer  shares rose as much as 3.5% on Monday, reaching their highest level in 14 months, after the United States government said that a $25 million glyphosate decision against the company should be reversed.

Bayer shares up 3.5% after U.S. government's backing in glyphosate lawsuit

The U.S. Environmental Protection Agency and the Justice Department said a federal appeals court should reverse a lower court verdict finding Bayer AG liable in the case of a California man who blamed its Roundup weed killer for his cancer.

U.S. government says verdict in Bayer's Roundup case should be reversed

Bayer AG  on Monday said it has asked a U.S. federal appeals court to throw out a $25 million judgment it was ordered to pay to a California man who blamed the company's Roundup weed killer for his cancer.

Bayer asks U.S. appeals court to reverse $25 million Roundup verdict

Adding Bayer To My Repurchase List

Germany's Bayer  has agreed with plaintiffs to postpone its next two U.S. lawsuits over the alleged cancer-causing effects of its glyphosate-based weed killers to allow more time for talks on a settlement.

News for Bayer AG Stock (BAYRY)